Endothelin Receptor Antagonists in the Treatment of Prostate Cancer

Lance K. Lassiter, Michael A Carducci

Research output: Contribution to journalReview article

Abstract

The endothelin (ET) axis represents a novel and exciting target in the treatment of prostate cancer. ET-1, acting primarily through the endothelin A receptor (ETA), is integrally involved in multiple facets of prostate cancer progression, including cell growth, inhibition of apoptosis, angiogenesis, development and progression of bone metastases, and mediation of pain responses. Clinical trials with the ETA antagonist, atrasentan, have demonstrated good tolerability, with the most common adverse events being headache, rhinitis, and peripheral edema. These trials have demonstrated statistically significant improvements in pain measures, prostate-specific antigen (PSA) kinetics, biologic markers of bone changes, and development of bone metastases. There have also been consistent improvements in time to progression, although not always statistically significant. Ongoing studies in a variety of patient populations will better define the role of ET receptor antagonists in the treatment of men with prostate cancer. In this article, we review the biology and pathophysiology of the ET axis in prostate cancer, critically analyze the major clinical trials reported to date, and discuss some emerging data and how it may impact the way we proceed in the future with the development of this class of drugs in prostate cancer.

Original languageEnglish (US)
Pages (from-to)678-688
Number of pages11
JournalSeminars in Oncology
Volume30
Issue number5
DOIs
StatePublished - Oct 2003

Fingerprint

Prostatic Neoplasms
Bone Development
Endothelins
Clinical Trials
Neoplasm Metastasis
Therapeutics
Endothelin A Receptors
Pain
Endothelin-1
Prostate-Specific Antigen
Rhinitis
Headache
Edema
Biomarkers
Endothelin Receptor Antagonists
Apoptosis
Bone and Bones
Growth
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Endothelin Receptor Antagonists in the Treatment of Prostate Cancer. / Lassiter, Lance K.; Carducci, Michael A.

In: Seminars in Oncology, Vol. 30, No. 5, 10.2003, p. 678-688.

Research output: Contribution to journalReview article

@article{b80d2b358ec447ef8431c1a8771abc71,
title = "Endothelin Receptor Antagonists in the Treatment of Prostate Cancer",
abstract = "The endothelin (ET) axis represents a novel and exciting target in the treatment of prostate cancer. ET-1, acting primarily through the endothelin A receptor (ETA), is integrally involved in multiple facets of prostate cancer progression, including cell growth, inhibition of apoptosis, angiogenesis, development and progression of bone metastases, and mediation of pain responses. Clinical trials with the ETA antagonist, atrasentan, have demonstrated good tolerability, with the most common adverse events being headache, rhinitis, and peripheral edema. These trials have demonstrated statistically significant improvements in pain measures, prostate-specific antigen (PSA) kinetics, biologic markers of bone changes, and development of bone metastases. There have also been consistent improvements in time to progression, although not always statistically significant. Ongoing studies in a variety of patient populations will better define the role of ET receptor antagonists in the treatment of men with prostate cancer. In this article, we review the biology and pathophysiology of the ET axis in prostate cancer, critically analyze the major clinical trials reported to date, and discuss some emerging data and how it may impact the way we proceed in the future with the development of this class of drugs in prostate cancer.",
author = "Lassiter, {Lance K.} and Carducci, {Michael A}",
year = "2003",
month = "10",
doi = "10.1016/S0093-7754(03)00353-1",
language = "English (US)",
volume = "30",
pages = "678--688",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Endothelin Receptor Antagonists in the Treatment of Prostate Cancer

AU - Lassiter, Lance K.

AU - Carducci, Michael A

PY - 2003/10

Y1 - 2003/10

N2 - The endothelin (ET) axis represents a novel and exciting target in the treatment of prostate cancer. ET-1, acting primarily through the endothelin A receptor (ETA), is integrally involved in multiple facets of prostate cancer progression, including cell growth, inhibition of apoptosis, angiogenesis, development and progression of bone metastases, and mediation of pain responses. Clinical trials with the ETA antagonist, atrasentan, have demonstrated good tolerability, with the most common adverse events being headache, rhinitis, and peripheral edema. These trials have demonstrated statistically significant improvements in pain measures, prostate-specific antigen (PSA) kinetics, biologic markers of bone changes, and development of bone metastases. There have also been consistent improvements in time to progression, although not always statistically significant. Ongoing studies in a variety of patient populations will better define the role of ET receptor antagonists in the treatment of men with prostate cancer. In this article, we review the biology and pathophysiology of the ET axis in prostate cancer, critically analyze the major clinical trials reported to date, and discuss some emerging data and how it may impact the way we proceed in the future with the development of this class of drugs in prostate cancer.

AB - The endothelin (ET) axis represents a novel and exciting target in the treatment of prostate cancer. ET-1, acting primarily through the endothelin A receptor (ETA), is integrally involved in multiple facets of prostate cancer progression, including cell growth, inhibition of apoptosis, angiogenesis, development and progression of bone metastases, and mediation of pain responses. Clinical trials with the ETA antagonist, atrasentan, have demonstrated good tolerability, with the most common adverse events being headache, rhinitis, and peripheral edema. These trials have demonstrated statistically significant improvements in pain measures, prostate-specific antigen (PSA) kinetics, biologic markers of bone changes, and development of bone metastases. There have also been consistent improvements in time to progression, although not always statistically significant. Ongoing studies in a variety of patient populations will better define the role of ET receptor antagonists in the treatment of men with prostate cancer. In this article, we review the biology and pathophysiology of the ET axis in prostate cancer, critically analyze the major clinical trials reported to date, and discuss some emerging data and how it may impact the way we proceed in the future with the development of this class of drugs in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0142030955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142030955&partnerID=8YFLogxK

U2 - 10.1016/S0093-7754(03)00353-1

DO - 10.1016/S0093-7754(03)00353-1

M3 - Review article

VL - 30

SP - 678

EP - 688

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -